
    
      This is a first-in-humam, randomized, double-blind, placebo-controlled study in a healthy
      population. Up to 7 single ascending doses (cohorts 1 to 7) will be studied to determine the
      safety and tolerability of ALD1910. Approximately 96 healthy male and female participants are
      planned for the study, 64 for Part A and 32 for Part B.
    
  